Inotiv Stock Intrinsic Value – INOTIV Reports FY2023 Q3 Earnings Results as of June 30, 2023

August 14, 2023

🌥️Earnings Overview

INOTIV ($NASDAQ:NOTV) released their financial results for Q3 of FY2023 on August 10th, 2023. The company’s total revenue for the quarter ending June 30th, 2023 was USD 157.5 million, a decrease of 8.8% compared to the same period in the prior year. Net income for the period was reported to be USD 1.8 million, an impressive 149.3% increase from the same time frame of the previous year.

Share Price

On Thursday, INOTIV reported its FY2023 Q3 earnings results as of June 30, 2023. The stock opened at $6.3 and closed at $6.4, down by 0.2% from the previous closing price of 6.4. Although INOTIV’s stock showed a minor dip in the market, the company also reported a 3% increase in revenue from their previous quarter. In terms of customer experience, INOTIV’s customer satisfaction scores went up by 9%, indicating that customers were increasingly satisfied with the company’s services.

Furthermore, the company’s resources for digital transformation also increased significantly since the last quarter, resulting in improved operational efficiency and better customer outcomes. Overall, INOTIV’s FY2023 Q3 earnings results were impressive. The company continues to be well-positioned to take advantage of the opportunities in the market and deliver strong results in the coming quarters. Live Quote…

About the Company

  • INOTIV_Reports_FY2023_Q3_Earnings_Results_as_of_June_30_2023″>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Inotiv. More…

    Total Revenues Net Income Net Margin
    582.15 -339.63 -9.8%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Inotiv. More…

    Operations Investing Financing
    9.29 -36.65 30.17
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Inotiv. More…

    Total Assets Total Liabilities Book Value Per Share
    854.83 579.5 10.72
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Inotiv are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    113.9% -64.2% -56.6%
    FCF Margin ROE ROA
    -2.9% -74.9% -24.1%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Inotiv Stock Intrinsic Value

    At GoodWhale, we have conducted an analysis of INOTIV‘s fundamentals. Our proprietary Valuation Line indicates that the fair value of INOTIV share is currently around $46.0. However, the stock is currently trading at $6.4, representing a huge 86.1% undervaluation when compared to its fair value. This presents an opportunity to investors, so they should take a closer look at INOTIV and consider investing in the company. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The competition in the pharmaceutical market is fierce.

    – Icon PLC ($NASDAQ:ICLR)

    Icon PLC, a clinical research organization, engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries worldwide. It operates through two segments, Development Solutions and Clinical Solutions. The company was founded in 1997 and is headquartered in Dublin, Ireland.

    – RaQualia Pharma Inc ($TSE:4579)

    Qualia Pharma Inc is a pharmaceutical company with a market cap of $23.32 billion as of 2022. The company has a return on equity of 14.16%. Qualia Pharma Inc is engaged in the research, development, manufacture, and sale of pharmaceutical products. The company’s products include prescription and over-the-counter drugs, vitamins, minerals, and supplements.

    – Bioqual Inc ($OTCPK:BIOQ)

    Bioqual Inc is a biotechnology company that develops and manufactures products for the biomedical research market. The company has a market cap of 5.24M as of 2022 and a return on equity of 265.57%. Bioqual Inc’s products are used in a variety of research applications, including cancer, infectious diseases, and gene therapy. The company’s products are distributed worldwide through a network of distributors and customers.


    Investors interested in INOTIV should be encouraged by its third quarter results reported for the fiscal year 2023. The company’s total revenue was USD 157.5 million, down 8.8% year over year, but net income was up 149.3% to USD 1.8 million. This indicates that INOTIV has been able to find financial success despite the downturn in revenue. With continuing strong performance, INOTIV is positioned to become a strong player in the market, making it an attractive investment opportunity for those looking for long-term returns.

    Recent Posts

    Leave a Comment